Drug Trial Radar · NCT07656727
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
Nov 30, 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- BioAge Labs, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.
Conditions
- Obesity and Cardiovascular Risk
Interventions
Oral BGE-102Drug
Capsules
Oral Placebo Matching BGE-102Drug
Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in hsCRP (Dose A)Time frame: Week 12
- Percent change in hsCRP (Dose B)Time frame: Week 12
- Percent change in hsCRP (Dose C)Time frame: Week 12
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Site 108
Chandler, Arizona
Site 115
Peoria, Arizona
Site 110
Tucson, Arizona
Site 100
Rogers, Arkansas
Site 109
Maitland, Florida
Site 102
Miami, Florida
Site 104
Port Orange, Florida
Site 103
Lexington, Kentucky
Site 106
Rockville, Maryland
Site 113
Kansas City, Missouri
Site 116
Las Vegas, Nevada
Site 111
Hartsdale, New York
Site 112
Austin, Texas
Site 114
Dallas, Texas
Site 101
San Antonio, Texas
Site 117
Sugar Land, Texas
Site 105
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.